Profile of temsirolimus in the treatment of advanced renal cell carcinoma
OncoTargets and Therapy2010Vol. 3, pp. 191–191
Citations Over TimeTop 22% of 2010 papers
Abstract
Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trials temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
Related Papers
- → Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa(2010)132 cited
- → Temsirolimus, an mTOR Inhibitor for Treatment of Patients With Advanced Renal Cell Carcinoma(2008)49 cited
- → Clinical Development of Temsirolimus, a Novel mTOR Inhibitor, for Treatment of Advanced Malignancies(2009)1 cited
- → Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients(2011)
- → 369 Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib(2012)